Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors

Area of Science:

• Natural Products Chemistry
• Medicinal Chemistry
• Oncology

Background:

• Dolastatin 10, a potent anticancer peptide from Dolabella auricularia, has inspired the development of novel cancer therapeutics.
• Structural modifications of dolastatin 10 have led to successful antibody-drug conjugates (ADCs), such as Adcetris (desmethylauristatin E).
• There is an ongoing need for new anticancer agents with enhanced potency for ADC development.

Purpose of the Study:

• To discover and synthesize a new class of dolastatin 10 analogs, termed quinstatins.
• To evaluate the anticancer activity of quinstatins for their potential use in chemically unique ADCs.
• To explore the structure-activity relationship of quinstatins.

Main Methods:

• Chemical synthesis of novel quinstatin analogs (compounds 2-8) derived from dolastatin 10.
• Modification involved replacing the C-terminal Dolapro-dolaisoleuine (Doe) unit with a quinoline moiety.
• Biological evaluation of synthesized compounds using cancer cell line assays.

Main Results:

• Discovery of quinstatins, a new subset of auristatin analogs.
• Quinstatins demonstrated potent cancer cell growth inhibition at low or subnanomolar concentrations.
• The novel quinoline modification is crucial for the observed high potency.

Conclusions:

• Quinstatins represent a promising new class of anticancer agents derived from dolastatin 10.
• Their potent activity makes them suitable candidates for the development of novel antibody-drug conjugates (ADCs).
• Further research into quinstatins could lead to next-generation cancer therapeutics.